Authors
Praloy Basu
Published in
Cureus. Volume 18. Issue 5. Pages e108998. Epub May 16, 2026.
Abstract
Gastric cancer remains a major global cause of cancer mortality despite improvements in surgery, perioperative chemotherapy, radiotherapy, and supportive care. For resectable locally advanced gastric and gastroesophageal junction adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) has become a major standard of care; however, recurrence remains frequent, reflecting the persistence of micrometastatic disease and biological resistance. Immune checkpoint inhibitors have transformed the management of advanced gastric cancer and are now being investigated in curative-intent settings. The rationale for earlier use is strong: intact tumor antigen, preserved lymphatic priming, and potential eradication of micrometastases may enhance immune-mediated control. This review discusses the emerging role of immunotherapy in neoadjuvant, adjuvant, and perioperative gastric cancer management, with a particular focus on pivotal trials including DANTE, Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab (NEONIPIGA), KEYNOTE-585, ATTRACTION-5, CheckMate-577, and MATTERHORN. MATTERHORN represents the most important recent phase III advance, showing that perioperative durvalumab plus FLOT significantly improves event-free survival compared with FLOT alone in resectable gastric or gastroesophageal junction adenocarcinoma. Future integration of immunotherapy will require careful biomarker selection, interpretation of survival endpoints, toxicity management, and adaptation to regional treatment standards.
PMID:
42311712
Bibliographic data and abstract were imported from PubMed on 18 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0